The typical maintenance dose for semaglutide weight loss is 2.4 mg once weekly, while treatment usually starts at 0.25 mg once weekly. The dose is increased gradually, not taken at the full maintenance level from the first injection.
But what happens if 2.4 mg doesn't produce the result you hoped for? Most dosing charts stop at that familiar target. A more useful answer explains why 2.4 mg became standard, how to handle a plateau, and why the approval of 7.2 mg Wegovy HD in 2026 has changed the question from “What's the usual dose?” to “What dose is appropriate and tolerable for this person?”
Why Semaglutide Dosing Matters for Weight Loss
A person beginning semaglutide may take 0.25 mg once weekly during the first four weeks, even though the long-term reference dose is 2.4 mg once weekly. That opening dose can feel underwhelming, especially when appetite changes are modest. It isn't meant to deliver the full weight-management effect immediately. It gives the body time to adjust before each increase.
The dose affects two things at once: how strongly appetite and fullness signals change, and how likely gastrointestinal effects are to become difficult. Increasing faster may sound efficient, but nausea, vomiting, diarrhea, or constipation can make eating, drinking, and staying on treatment harder. A slower schedule can be the more effective route if it helps you continue treatment consistently.
Practical rule: The right dose isn't automatically the highest dose. It's the dose that provides a useful response without creating side effects you can't manage.
The question “how much semaglutide for weight loss” therefore has four parts:
- Titration logic: why the dose rises in stages rather than all at once.
- Clinical evidence: why researchers and regulators centered weight management around 2.4 mg.
- Safety management: how symptoms should influence the timing of dose increases.
- Provider conversations: how your health history, response, access, and treatment goals shape the plan.
Your first six months may include several different experiences. Early weeks can focus mostly on tolerance. Later weeks may bring a clearer appetite response. Some people reach the standard maintenance dose, while others remain at a lower dose because it works well or because higher doses cause unacceptable symptoms. A prescription should be individualized, not copied from someone else's injection schedule.
What Semaglutide Is and Why Dose Is Built Step by Step
Semaglutide is a GLP-1 receptor agonist, meaning it acts on a hormone pathway involved in appetite regulation, fullness, and food intake. A useful analogy is a dimmer switch. The medication does not just flip hunger from “on” to “off.” It gradually changes the intensity of appetite signals and helps some people feel satisfied with less food.
The body also has to adapt to changes in gastrointestinal function. That's one reason clinicians raise the dose in stages. A gradual increase gives symptoms such as nausea, reduced appetite, constipation, or diarrhea a chance to settle before the next step. The principle applies across the dosing range, from the first low dose to the standard maintenance dose and, for eligible adults, the higher-dose formulation.
For a plain-language overview of the medication itself, see this guide to what semaglutide is. Readers interested in how GLP-1 treatment may develop over time can also explore the future of weight loss.
Why a low starting dose can be useful
Starting low doesn't mean the medication is failing. It's more like learning to drive in an empty parking lot before entering heavy traffic. The opening dose establishes tolerance. Later increases test whether a stronger effect is helpful and manageable.
The standard adult schedule begins at 0.25 mg once weekly for four weeks, then increases every four weeks through 0.5 mg, 1.0 mg, and 1.7 mg, before reaching 2.4 mg weekly at about week 16, according to the STEP 1 trial report. If symptoms flare, a clinician may keep you at the current dose longer rather than treating the calendar as fixed.
This “low and slow” approach matters because treatment success depends on more than the number printed on the prescription. A dose that supports steady use, adequate hydration, and reasonable nutrition may be more valuable than a higher dose that forces repeated interruptions.
The Standard Semaglutide Titration Schedule
The standard schedule uses one injection each week and usually holds each dose for four weeks. The aim is to reach 2.4 mg weekly, or the highest dose you can tolerate safely and consistently.
| Week Range | Weekly Dose | Purpose |
|---|---|---|
| Weeks 1 to 4 | 0.25 mg | Initial tolerance and adjustment |
| Weeks 5 to 8 | 0.5 mg | Early appetite and treatment response |
| Weeks 9 to 12 | 1.0 mg | Continued dose building |
| Weeks 13 to 16 | 1.7 mg | Preparation for maintenance |
| Week 17 onward | 2.4 mg | Standard maintenance target |
The schedule is a guide, not a race. If nausea, vomiting, or diarrhea becomes troublesome, your prescriber may delay the next increase by two to four weeks, depending on your symptoms and overall health. Some people may stay at a lower tolerated dose rather than forcing the next step.
The weekly cadence stays the same at every level. You don't take the starting dose daily, and you don't divide a weekly dose into improvised smaller injections unless your prescriber gives specific instructions. The amount changes over time, but the routine remains one scheduled injection each week.
How to think about each stage
At 0.25 mg, the main question is tolerance. You're learning how your body reacts, not judging the final effect. At 0.5 mg and 1.0 mg, appetite changes may become more noticeable, but the medication is still being built toward its reference maintenance level.
At 1.7 mg, the focus shifts toward whether the expected benefits justify moving to the standard maintenance dose. By 2.4 mg, you and your provider can evaluate the balance among weight trend, hunger control, side effects, adherence, and health goals.
For a visual version of the schedule, review this semaglutide titration schedule. Never borrow another person's schedule, even if the prescription name and pen appear identical. Your medical history and response determine whether the next increase is appropriate.
What the Clinical Trials Say About the 2.4 mg Dose
The importance of 2.4 mg weekly comes from clinical evidence, not from a convenient round number. In the STEP 1 trial, 1,961 adults with obesity or overweight without diabetes were randomized. After 68 weeks, participants receiving semaglutide lost 14.9% of baseline body weight, compared with 2.4% with placebo. The estimated treatment difference was 12.4 percentage points. These results are reported in the STEP 1 publication.
The same trial found that 86.4% of participants receiving semaglutide achieved at least 5% weight loss, compared with 31.5% receiving placebo. Those figures help explain why clinicians and regulators use 2.4 mg as the reference maintenance dose for Wegovy-style weight management.
The trial does not mean every person will lose 14.9%. Participants differ in biology, adherence, starting weight, health conditions, medication use, eating patterns, activity, and tolerance. The study also included lifestyle counseling, so results in routine care may not match trial outcomes.
What the evidence does and doesn't prove
The strongest verified takeaway is the overall result at the standard maintenance dose. The available data here don't provide a complete dose-by-dose table with average weight loss, 10% thresholds, and 15% thresholds for every intermediate dose. It would be misleading to fill those gaps with guessed averages.
| Maintenance Dose | Avg. Weight Loss | ≥10% Loss | ≥15% Loss |
|---|---|---|---|
| 2.4 mg weekly | 14.9% at 68 weeks in STEP 1 | Not specified in the verified data | Not specified in the verified data |
The result also came with practical limitations. Gastrointestinal side effects can lead some participants to stop treatment, and benefit depends on taking the medication as directed. A person who remains at a lower dose because of symptoms may experience a different response from someone who reaches 2.4 mg and maintains it.
That's why the standard dose should be viewed as a reference target, not a promise. It establishes the dose used in key evidence, while clinical care still asks a more personal question: what level produces meaningful progress for you without making treatment unsustainable?
When 2.4 mg Is Not Enough and Higher Doses Enter the Picture
What should you do when weight loss slows at 2.4 mg? A plateau does not prove that semaglutide has stopped helping. Inconsistent dosing, changes in food intake or activity, medication interactions, medical conditions, and the body's adaptation to weight reduction can all affect progress. A clinician should examine these factors before considering a higher dose.
The discussion changed in 2026, when the FDA approved Wegovy HD, a 7.2 mg once-weekly formulation for adults with obesity. The approval relied on a 72-week STEP UP program involving 1,407 adults. Company-reported trial data found about 21% average weight loss among people who stayed on treatment, while 31.2% achieved at least 25% weight loss. The evidence and approval details appear in the FDA's 2026 approval announcement for Wegovy HD.
What a higher-dose discussion should include
Wegovy HD has a defined formulation, prescribing information, and clinical evidence. That makes it different from increasing a dose independently or using a compounded product with an improvised concentration. Even with an approved option, a higher dose may be unsuitable for someone whose current treatment is effective and manageable.
A provider may review:
- Response: Have you reached a meaningful plateau after consistent use?
- Tolerance: Can you manage current symptoms without dehydration, nutritional problems, or repeated missed doses?
- Health context: Could another medication or medical condition affect the decision?
- Coverage: Will insurance recognize the higher-dose product?
- Alternatives: Would keeping the current dose, changing the treatment plan, or improving adherence make more sense?
Higher dosing can increase gastrointestinal burden, so it requires the same step-by-step care as earlier titration. Therapies still in development may offer future choices, but they are not equivalent to approved treatments available through ordinary prescribing.
Treat a plateau as a reason to investigate causes first; dose escalation is one option among several.
Ask your provider, "What explains my plateau?", "What benefit would a higher dose add for me?", and "What symptoms would mean we should stop escalating?" These questions focus the discussion on expected benefit, safety, and a sustainable plan rather than requesting the strongest available dose.
Choosing Between Injectable, Oral, and Compounded Semaglutide
Patients often compare three very different options under the single name “semaglutide.” The weekly injectable form has the clearest established weight-management dosing path in the verified evidence here, moving from 0.25 mg toward 2.4 mg weekly. Oral semaglutide offers a tablet-based route, while compounded products can vary in concentration, formulation, and oversight.
The oral option deserves a careful discussion because recent evidence reported significant weight loss with 25 mg oral semaglutide in 2025. The OASIS 4 summary describes that evidence and the broader shift toward oral treatment. A tablet may remove injection discomfort, but it still requires reliable daily use and may have administration instructions that don't fit every routine.
| Format | Dosing Range | Frequency | Cost & Coverage | Safety Notes |
|---|---|---|---|---|
| Injectable semaglutide | Starts at 0.25 mg, standard maintenance 2.4 mg; higher-dose Wegovy HD is 7.2 mg | Weekly | Depends on product and insurance | Use prescribed product and titration |
| Oral semaglutide | Oral weight-management evidence includes 25 mg | Daily | Depends on product and insurance | Follow product-specific administration instructions |
| Compounded semaglutide | Variable | Varies by prescription | May be considered when access or cost is a barrier | Not interchangeable with an FDA-approved product; requires prescriber oversight |
Matching the format to real life
Choose based on more than needle preference. Consider whether you can maintain a daily tablet routine, whether your pharmacy can reliably fill the prescription, whether your insurance covers the product, and whether the source is a legitimate pharmacy.
Compounded semaglutide raises additional quality and dosing questions. It may be discussed in limited access situations, but it isn't automatically equivalent to an approved product. Patients should verify the pharmacy and follow a clinician's instructions rather than converting milligrams, milliliters, or “units” on their own.
Food choices also matter when appetite is reduced. A structured meal plan for GLP-1 users can help organize protein, fluids, and manageable portions, but nutrition advice should still be adapted to your symptoms and medical needs. For a focused comparison of routes, see oral versus injectable semaglutide.
Side Effects by Dose and How to Manage Them
Semaglutide side effects often become most noticeable during or soon after an increase. The dominant category is gastrointestinal: nausea, vomiting, diarrhea, and constipation. Fatigue, headache, and injection-site reactions can also occur.
The same symptom can mean different things in different people. Mild nausea that improves may be manageable, while repeated vomiting can make continued escalation unsafe. Tolerability is part of dose selection, not an inconvenience to ignore.
| Dose Phase | Common Side Effects | Management Tips |
|---|---|---|
| 0.25 mg | Early nausea, appetite change, fatigue, headache | Eat smaller meals, drink fluids, and track symptoms |
| 0.5 mg to 1.0 mg | Nausea, constipation, diarrhea, reduced appetite | Avoid forcing the next increase if symptoms remain active |
| 1.7 mg | More noticeable gastrointestinal symptoms in some people | Discuss delaying escalation and review hydration |
| 2.4 mg | Ongoing nausea, vomiting, diarrhea, constipation, fatigue | Continue only if benefits and tolerability remain acceptable |
| 7.2 mg Wegovy HD | Higher-dose gastrointestinal monitoring is especially important | Use only under appropriate prescribing and follow-up |
Practical ways to reduce discomfort
Try smaller, lower-fat meals rather than large portions. Eat slowly, stop when you feel full, and keep fluids available throughout the day. If constipation develops, ask your provider what changes are appropriate rather than adding a laxative without checking for interactions or underlying problems.
Some people prefer to schedule an injection before a quieter day, but the medication should still be taken according to the prescribed weekly routine. Don't skip, double, or reposition doses to compensate for symptoms without medical instructions.
Stop and call: Persistent vomiting, signs of dehydration, severe abdominal pain, or visual changes warrant prompt contact with a healthcare professional.
Higher-dose treatment requires stricter monitoring because increasing the amount can intensify symptoms. If you can't keep fluids down, feel faint, produce very little urine, or develop severe pain, seek urgent medical guidance. A dose increase should pause until the situation is evaluated.
Keep a simple log with the injection date, dose, nausea level, bowel symptoms, fluid intake, and weight trend. That record gives your provider something more useful than a vague memory of “feeling sick after the shot.”
Talking to a Provider About Your Semaglutide Dose
Dose selection works best as an ongoing conversation. Your provider needs more than your current weight. They'll consider your health history, previous attempts at weight management, other medications, symptoms, treatment goals, and ability to follow the schedule.
Bring these questions to an appointment:
- Treatment target: What outcome would count as meaningful progress for me?
- Dose plan: What is the planned starting dose, and what would make us delay an increase?
- Medical history: Do thyroid problems, pancreatitis, gastroparesis, or other conditions change the plan?
- Medication review: Could any of my current medications affect appetite, digestion, glucose, or weight?
- Plateau review: Have I used the current dose consistently long enough to evaluate the response?
- Higher-dose suitability: Would Wegovy HD be clinically appropriate, available, and covered?
- Safety plan: Which symptoms require a message, an urgent call, or emergency care?
At follow-up, your provider may review weight trends, appetite, meal tolerance, bowel habits, hydration, injection technique, and adherence. Laboratory monitoring may be appropriate depending on your health history and symptoms. A plateau should prompt a structured review before an automatic dose increase.
Prepare between appointments
Write down your injection dates and exact prescribed dose. Note whether you missed doses, experienced vomiting or diarrhea, struggled with fluids, or noticed changes in hunger and fullness. Bring the medication box or pharmacy information if you're unsure which formulation you received.
Use an approved prescription channel whenever possible. Don't substitute a compounded product, change concentrations, or calculate a higher dose without prescriber oversight. The safest answer to “how much semaglutide for weight loss” is the dose that fits your evidence-based treatment plan, health profile, response, and ability to continue.
Weight Method offers telehealth consultations with licensed providers, provider-guided semaglutide or tirzepatide treatment, ongoing messaging, progress tracking, and dose adjustments when clinically appropriate. Visit Weight Method to complete the online assessment and discuss whether supervised GLP-1 treatment fits your goals.